About ALS-357

ALS-357 is a natural product we are developing that has demonstrated specific anti-tumor activity against malignant melanoma. It has a unique mechanism of action that disrupts mitochondrial membrane function and is associated with the intrinsic, mitochondria-mediated pathway of apoptosis. ALS-357 has shown promise in both in vivo and in vitro preclinical studies. In preclinical animal studies, ALS-357 has been shown to concentrate in tumors, resulting in rapid tumor regression with no observable toxicity to the animal even at high doses. In addition, preclinical studies have shown that direct injection of ALS-357 into grafted human tumors induced apoptosis, or programmed cell death, within the tumors.

A Phase I/II study in which both safety and efficacy outcomes will be measured is currently being planned.